AI

Lab automation
#AI #Automata #Automation / robotics #Danaher Corporation

Beckman Coulter partners with Automata on lab automation 

Danaher’s Beckman Coulter Life Sciences has partnered with robotics company Automata to accelerate AI-ready laboratory automation.  The strategic partnership will integrate Beckman Coulter Life Sciences’ liquid handling, genomic and cell analysis technologies with Automata’s AI-ready automation platform, enabling faster, more consistent and more scalable experimentation for research organisations.  The companies hope their work will bring next generation… Read More

#Business & Investment #News

#AI #Biotech #Breast cancer #Clinical trial #Obesity

Why AI, obesity and breast cancer will dominate 2026

The latest episode of the DDW podcast is available to listen to below. This week, Bruno Quinney speaks to DDW Editor Reece Armstrong and Deputy Editor Diana Turner to look ahead to the world of drug discovery, pharma and biotech in 2026. They explore why AI will continue to dominate… Read More

#Featured Podcasts #Podcasts

#AI #Biomarkers #Machine learning #SLAS2026

The science behind SLAS2026 

DDW Editor Reece Armstrong examines some of the science that has emerged in the last year that is driving the conversations at SLAS 2026. SLAS always provides a great opportunity to assess what topics are in the minds of scientists within the drug discovery and development sector and this year is no different. The exhibition’s… Read More

#Exclusive Content

#AI #Drug discovery #United States

From the Editor: A year in turmoil

For the drug discovery, and wider pharmaceutical industry, the year of 2025 can be characterised by the words turmoil and uncertainty.   The second coming of President Trump brought with it a flurry of executive orders, tariffs and global bargaining that placed the US in a position where it attempted to dictate… Read More

#Exclusive Content #Opinion

#AI #Organoids #Rare diseases

Partnership set to advance organoid-based disease models  

Cell technology company iXCells Biotechnologies has partnered with Rosebud Biosciences to advance organoid-based models for rare diseases.  The partnership will set out to develop a personalised, human-based approach for predicting drug safety and informing translational decision-making in rare diseases.  iXCells will integrate Rosebud’s organoid generation and characterisation expertise into its existing iPSC solutions, enabling access to… Read More

#Business & Investment #News

#AI #Clinical trial #Drug discovery #Parse Biosciences

Life science partnership to improve AI-driven drug discovery  

Life sciences company Parse Biosciences has partnered with research institute Graph Therapeutics to create what it says is one of the largest and most comprehensive immune cell perturbation atlases.  The collaboration will leverage Graph's lab-in-the-loop platform with Parse's GigLab to profile hundreds of millions of cells from patients with immune diseases under systematic perturbation, making the… Read More

#Business & Investment #News

Artificial Intelligence
#AI #AI / data analytics / healthtech / informatics #Drug discovery

Insitro acquires AI biotech to develop drug discovery platform 

AI therapeutics company insitro has acquired biotechnology company CombinAbleAI to complete its AI platform for drug discovery and design.   The platform, known as TherML (Therapeutic Machine Learning), will enable insitro to accelerate the generation of clinic-ready assets and reduce late-stage development risk. The company’s enhanced platform will reportedly guide both modality selection and molecular design from target discovery through developability assessment.  "Drug discovery has traditionally… Read More

#Business & Investment #News

#AI #Heart disease #Lung disease #Qureight

Qureight appoints Rebecca Simmons as COO 

Techbio company Qureight has appointed Rebecca Simmons as the company’s Chief Operating Officer.  Simmons will be responsible for scaling the company’s global business operations and leading sustainable growth initiatives. The appointment comes as Qureight aims to drive adoption and integration of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials for… Read More

#News

Therapeutic antibodies
#Absci #AI #AI / data analytics / healthtech / informatics #Antibody-based therapeutics #Biologics #Generative AI #Machine learning

How the next generation of AI is reshaping antibody drug discovery

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Machine learning: developing next generation antibody therapeutics’. Ben Holland, CTO and Co-Founder of Antiverse, discusses how artificial intelligence and… Read More

#Featured Podcasts #Podcasts

#AI #Bayer #Cradle #Drug discovery

Bayer partners with Cradle to advance AI-led drug discovery 

Pharma giant Bayer has signed a three-year strategic collaboration with biotech company Cradle to advance AI-enabled antibody discovery and optimisation.  Bayer aims to implement Cradle’s AI software platform, used for protein engineering, to scale its drug discovery and development efforts. The company intends to integrate Cradle’s platform with existing R&D… Read More

#Business & Investment #News

#AI #Heart disease #Lung disease #Qureight

Qureight appoints Dr Steven Bishop as CMO 

Techbio company Qureight has announced the appointment of Dr Steven Bishop as Chief Medical Officer.  Bishop previously served as Chief Data Officer for the company, which uses AI-powered CT imaging biomarkers and its clinical data management platform to advance understanding of lung and heart diseases.  As CMO, Bishop… Read More

#News

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

DDW Highlights: 23 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated… Read More

#Podcasts

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

This week in Drug Discovery (15 – 19 December) 

News round-up for 15 – 19 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated antibodies have been tolerated by human immune cells.  The top stories:    Scientists discover hidden molecular switch that… Read More

#News

Chemify's Chemifarm
#AI #Chemify #Drug discovery #Tuberculosis

Chemify receives $1.6 million to advance TB drug discovery 

Scottish tech company Chemify has received $1.6 million from the Gates Foundation to continue the discovery of small molecules for tuberculosis (TB).  Building on a successful collaboration with Lgenia, the expanded project will leverage Chemify’s automated platform to design and synthesise new drug leads, aiming to address one of the world’s most urgent infectious diseases. … Read More

#Business & Investment #News

Artificial intelligence
#AI #Drug discovery #Gene synthesis #Synthetic biology

How AI is transforming gene synthesis and genome engineering 

Ajay Gannerkote, President, Integrated DNA Technologies examines how AI is helping to advance the drug discovery landscape. In the past decade, few fields in biotechnology have evolved as dramatically as gene synthesis and genome engineering.  The evolution of digital technologies, particularly the advent of artificial intelligence (AI), has resulted in a… Read More

#Exclusive Content

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #DDW Highlights podcast #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

DDW Highlights: 16 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative treatments showed potential to treat neurodegenerative diseases, allergies and arthritis. Elsewhere,… Read More

#Podcasts